Treatment effect of deferiprone and desferrioxamine in beta thalassemia major
Not Applicable
- Conditions
- Major Thalassemia.Beta thalassaemia
- Registration Number
- IRCT138810203032N1
- Lead Sponsor
- Mazndaran University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
1- Confirmed major thalassemia by Hemoglubin elctrophoresis
2- Age ranged 5-30 years
3- Serum ferritin level more than 3000 ng/ml
4- Written consent from patients or parents
Exclusion criteria:
1- Disagreement of patients or parents for begining of treatment
2- Deferiprone sensitivity
3- Desferrioxamine sensitivity
3
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum ferritin. Timepoint: 6 months. Method of measurement: Immuno Radiaometric Assay.;Left ventricle ejection fraction. Timepoint: 6 months. Method of measurement: Echocardiography.
- Secondary Outcome Measures
Name Time Method Hemoglobin. Timepoint: 6 months. Method of measurement: Electronic counter.;AST. Timepoint: 6 months. Method of measurement: PARS AZMUN Kit.;ALT. Timepoint: 6 months. Method of measurement: PARS AZMUN Kit.